CR6620A - Amino acidos biciclicos como agentes farmaceuticos - Google Patents

Amino acidos biciclicos como agentes farmaceuticos

Info

Publication number
CR6620A
CR6620A CR6620A CR6620A CR6620A CR 6620 A CR6620 A CR 6620A CR 6620 A CR6620 A CR 6620A CR 6620 A CR6620 A CR 6620A CR 6620 A CR6620 A CR 6620A
Authority
CR
Costa Rica
Prior art keywords
bicycle
acids
amino
pharmaceutical agents
diseases
Prior art date
Application number
CR6620A
Other languages
English (en)
Inventor
Clive Blackemore David
Marie Receveur Jean
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6620A publication Critical patent/CR6620A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Abstract

Se trata de compuestos de aminoacidos biciclicos utiles en el tratamiento de la epilepsia, lagunas mentales, hipoquinesia, enfermedades craneales, neurodegenerativas, depresion, ansiedad, panico, dolor, artritis, enfermedades neuropatologicas y desordenes del sueno.
CR6620A 1999-10-20 2002-04-18 Amino acidos biciclicos como agentes farmaceuticos CR6620A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20

Publications (1)

Publication Number Publication Date
CR6620A true CR6620A (es) 2004-02-02

Family

ID=22578159

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6620A CR6620A (es) 1999-10-20 2002-04-18 Amino acidos biciclicos como agentes farmaceuticos

Country Status (50)

Country Link
US (2) US6689906B1 (es)
EP (2) EP1226110B1 (es)
JP (2) JP3632191B2 (es)
KR (2) KR100593349B1 (es)
CN (1) CN1165518C (es)
AP (2) AP2004003186A0 (es)
AR (2) AR026087A1 (es)
AT (2) ATE358116T1 (es)
AU (2) AU778871B2 (es)
BG (2) BG106719A (es)
BR (1) BR0014972B1 (es)
CA (1) CA2386297C (es)
CO (1) CO5280060A1 (es)
CR (1) CR6620A (es)
CU (1) CU23112A3 (es)
CZ (1) CZ295960B6 (es)
DE (2) DE60034157T2 (es)
DO (1) DOP2000000083A (es)
DZ (1) DZ3197A1 (es)
EA (1) EA005206B1 (es)
EC (1) ECSP045393A (es)
EE (1) EE200200211A (es)
ES (2) ES2237464T3 (es)
GE (1) GEP20043297B (es)
GT (2) GT200000183AA (es)
HK (1) HK1049826B (es)
HN (1) HN2000000224A (es)
HR (2) HRP20020428B1 (es)
HU (1) HUP0203325A3 (es)
IL (3) IL164060A0 (es)
IS (2) IS6348A (es)
MA (1) MA26842A1 (es)
MX (1) MXPA02003229A (es)
MY (1) MY127678A (es)
NO (2) NO20021780L (es)
NZ (1) NZ517961A (es)
OA (1) OA12070A (es)
PA (1) PA8505201A1 (es)
PE (1) PE20010740A1 (es)
PL (1) PL354607A1 (es)
PT (1) PT1226110E (es)
SI (1) SI1226110T1 (es)
SK (1) SK5232002A3 (es)
SV (1) SV2001000188A (es)
TR (2) TR200500221T2 (es)
TW (2) TW200505824A (es)
UA (1) UA72931C2 (es)
WO (1) WO2001028978A1 (es)
YU (2) YU73004A (es)
ZA (1) ZA200202543B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
JP3909842B2 (ja) * 2000-06-26 2007-04-25 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 睡眠障害のためのガバペンチン類似物
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
KR100618743B1 (ko) 2001-04-19 2006-08-31 워너-램버트 캄파니 엘엘씨 융합된 비사이클릭 또는 트리사이클릭 아미노산
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
NZ567711A (en) * 2001-06-11 2009-10-30 Xenoport Inc Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1469841A1 (en) 2002-01-31 2004-10-27 Warner-Lambert Company Alpha 2 delta ligands to treat tinnitus
BR0307906A (pt) * 2002-02-22 2004-12-21 Warner Lambert Co Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2
MXPA04012922A (es) * 2002-06-27 2005-03-31 Warner Lambert Co Procedimiento para tratar el trastorno de hiperactividad con deficit de atencion.
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
BR0313432A (pt) * 2002-08-15 2005-07-12 Pfizer Uso terapêutico de aminoácidos bicìclicos ou tricìclicos fundidos
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
KR20050085563A (ko) 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
JP2006513257A (ja) 2002-12-13 2006-04-20 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 線維筋痛症および他の障害を処置するためのプレガバリン誘導体
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
BRPI0414343A (pt) 2003-09-12 2006-11-07 Pfizer combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
JP5308350B2 (ja) 2006-12-22 2013-10-09 レコルダーティ アイルランド リミテッド α２δリガンドおよびＮＳＡＩＤを用いた下部尿路機能障害の併用療法
ES2531324T3 (es) 2007-09-28 2015-03-13 Daiichi Sankyo Co Ltd Intermedio para producir un derivado de gamma-aminoácido bicíclico
WO2010110361A1 (ja) 2009-03-26 2010-09-30 第一三共株式会社 二環性γ－アミノ酸誘導体の製造方法
HUE037046T2 (hu) 2011-06-08 2018-08-28 Daiichi Sankyo Co Ltd Eljárás biciklusos vegyület elõállítására iminium són keresztül
HUE035366T2 (en) 2011-06-08 2018-05-02 Daiichi Sankyo Co Ltd A method for the preparation of a bicyclic compound by Claisen rearrangement
CA2859003C (en) 2011-12-15 2016-11-01 Daiichi Sankyo Company, Limited Optical resolution method for bicyclic compound using asymmetric catalyst
ES2624314T3 (es) 2012-04-10 2017-07-13 Daiichi Sankyo Company, Limited Procedimiento de resolución óptica para compuestos bicíclicos usando enzima
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6635673B1 (en) 1997-10-27 2003-10-21 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents

Also Published As

Publication number Publication date
GT200000183AA (es) 2005-06-17
HRP20020428B1 (en) 2006-02-28
DE60034157T2 (de) 2007-12-13
HK1049826B (zh) 2005-02-25
NZ517961A (en) 2002-12-20
ATE293590T1 (de) 2005-05-15
ECSP045393A (es) 2004-10-23
TR200500221T2 (tr) 2005-03-21
HRP20020428A2 (en) 2005-02-28
JP3632191B2 (ja) 2005-03-23
EP1506955B1 (en) 2007-03-28
DE60019628D1 (de) 2005-05-25
PL354607A1 (en) 2004-01-26
PA8505201A1 (es) 2002-08-29
PE20010740A1 (es) 2001-07-27
JP2005036009A (ja) 2005-02-10
TWI225855B (en) 2005-01-01
AU778871B2 (en) 2004-12-23
ES2237464T3 (es) 2005-08-01
EA200200293A1 (ru) 2002-10-31
MXPA02003229A (es) 2002-09-30
BR0014972B1 (pt) 2011-09-06
AR045456A2 (es) 2005-10-26
NO20043663L (no) 2002-04-16
DOP2000000083A (es) 2002-03-30
CN1165518C (zh) 2004-09-08
JP3744928B2 (ja) 2006-02-15
CZ295960B6 (cs) 2005-12-14
TW200505824A (en) 2005-02-16
IL164060A0 (en) 2005-12-18
KR100593349B1 (ko) 2006-06-26
AU2005201268A1 (en) 2005-04-21
YU73004A (sh) 2005-11-28
US20040152779A1 (en) 2004-08-05
HK1049826A1 (en) 2003-05-30
PT1226110E (pt) 2005-07-29
DZ3197A1 (fr) 2001-04-26
AU1092001A (en) 2001-04-30
DE60019628T2 (de) 2006-01-19
KR20060013701A (ko) 2006-02-13
EP1226110A1 (en) 2002-07-31
ATE358116T1 (de) 2007-04-15
EA005206B1 (ru) 2004-12-30
CA2386297A1 (en) 2001-04-26
DE60034157D1 (de) 2007-05-10
AP2002002517A0 (en) 2002-06-30
NO20021780D0 (no) 2002-04-16
BG106719A (bg) 2003-02-28
EE200200211A (et) 2003-06-16
EP1506955A1 (en) 2005-02-16
US6835751B2 (en) 2004-12-28
AR026087A1 (es) 2002-12-26
US6689906B1 (en) 2004-02-10
KR20020040900A (ko) 2002-05-30
BR0014972A (pt) 2002-07-16
TR200201094T2 (tr) 2002-09-23
CZ20021310A3 (cs) 2003-05-14
ZA200202543B (en) 2003-09-23
CN1382118A (zh) 2002-11-27
OA12070A (en) 2003-11-10
ES2282785T3 (es) 2007-10-16
YU29302A (sh) 2005-06-10
CO5280060A1 (es) 2003-05-30
AP2004003186A0 (en) 2004-12-31
KR100566462B1 (ko) 2006-03-31
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
JP2003512348A (ja) 2003-04-02
MY127678A (en) 2006-12-29
IS6348A (is) 2002-04-17
SI1226110T1 (en) 2005-08-31
MA26842A1 (fr) 2004-12-20
EP1226110B1 (en) 2005-04-20
HUP0203325A3 (en) 2003-12-29
IS7497A (is) 2004-10-08
HUP0203325A2 (hu) 2003-02-28
HRP20040709A2 (en) 2004-12-31
UA72931C2 (uk) 2005-05-16
SV2001000188A (es) 2001-09-07
HN2000000224A (es) 2001-04-11
CA2386297C (en) 2010-02-09
IL149143A0 (en) 2002-11-10
BG108860A (en) 2006-03-31
NO20021780L (no) 2002-04-16
WO2001028978A1 (en) 2001-04-26
CU23112A3 (es) 2006-02-27
IL149143A (en) 2007-02-11
SK5232002A3 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
CR6620A (es) Amino acidos biciclicos como agentes farmaceuticos
BR9712651A (pt) ‡cidos gama-aminobutìricos substituìdos com agentes farmacêuticos.
ATE412415T1 (de) Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE552837T1 (de) Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen
HRP20090058A2 (en) Prodrugs of excitatory amino acids
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
PT888325E (pt) Novos amino acidos ciclicos como agentes farmaceuiticos
ES2185591T3 (es) Amino hererociclos utiles como agentes farmaceuticos.
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
DE602006009848D1 (de) Die regeneration von neuronen des zentralen nervensystems stimulierende peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung
DE60008293D1 (de) Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
PT1235573E (pt) Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais
ATE302000T1 (de) Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen
FR2834885B1 (fr) Procede de traitement notamment cosmetique d'une zone de la peau d'un sujet humain par voie tran-epidermique, par projection d'un liquide sous pression
HRP20040104A2 (en) Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
BRPI0417797A (pt) soro sangüìneo biologicamente ativo, métodos para produzi-lo e seus usos
RU2002109722A (ru) Способ лечения болевого синдрома у больных хроническими соматическими заболеваниями
TH60589A (th) โมโนไฮดรอกซีคาร์บามาเซพีนสำหรับใช้ในการเตรียมยาสำหรับการบำบัดรักษาความผิดปกติของอารมณ์และการมีสมาธิและความเจ็บปวดในโรคของระบบประสาท
UA42194A (uk) Спосіб введення лікарських препаратів, зосереджених в еритроцитарних контейнерах

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)